Low margins, tricky reimbursement issues and the difficulty of market penetration have traditionally made diagnostics unattractive to investors. However, with changes to healthcare economics, regulation and the adoption of companion diagnostic tests that are predictive for drug response, that may be about to change.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Forsman, R. Clin. Chem. 42, 813–816 (1996).
Habel, L.A. et al. Breast Cancer Res. [online] 8, R25 (2006) (doi: 10.1186/bcr1412).
Lazrou, J., Pomeranz, B.H. & Corey, P.N. J. Am. Med. Assoc. 279, 1200–1205 (1998).
Pirmohamed, M. Br. Med. J. 329, 15–19 (2004).
http://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4194M1.pdf.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Batchelder, K., Miller, P. A change in the market—investing in diagnostics. Nat Biotechnol 24, 922–926 (2006). https://doi.org/10.1038/nbt0806-922
Issue Date:
DOI: https://doi.org/10.1038/nbt0806-922
This article is cited by
-
Mechanisms of Disease: the genetic basis of coronary heart disease
Nature Clinical Practice Cardiovascular Medicine (2007)
